Demographic and clinical characteristics of episodes of allopurinol users (baseline with no atrial fibrillation; baseline was longest possible and at least 365 days)
| All episodes | Atrial fibrillation during the follow-up | |||
|---|---|---|---|---|
| Yes | No | p Value | ||
| Total, N (episodes) | 9244 | 1366 | 7878 | N/A |
| Age | 77.2 (7.0) | 77.0 (7.0) | 78.2 (7.2) | <0.0001 |
| Gender, N (%) | 0.81 | |||
| Male | 4020 (43.5) | 590 (43.2) | 3430 (43.5) | |
| Female | 5224 (56.5) | 776 (56.8) | 4448 (56.5) | |
| Race/ethnicity, N (%) | <0.0001 | |||
| White | 6595 (71.3) | 1049 (76.8) | 5546 (70.4) | |
| Black | 1434 (15.5) | 180 (13.2) | 1254 (15.9) | |
| Hispanic | 301 (3.3) | 39 (2.9) | 262 (3.3) | |
| Asian | 681 (7.4) | 71 (5.2) | 610 (7.7) | |
| Native American | 38 (0.4) | 5 (0.4) | 33 (0.4) | |
| Other/unknown | 48 (2.1) | 22 (1.6) | 173 (2.2) | |
| Region, N (%) | 0.016 | |||
| North-East | 1411 (15.3) | 236 (17.3) | 1175 (14.9) | |
| Mid-West | 2285 (24.7) | 350 (25.6) | 1935 (24.6) | |
| South | 3693 (40.0) | 542 (39.7) | 3151 (40.0) | |
| West | 1855 (20.1) | 238 (17.4) | 1617 (20.5) | |
| Charlson–Romano comorbidity score | 4.89 (3.77) | 5.44 (3.70) | 4.80 (3.77) | <0.0001 |